
|Videos|June 6, 2017
Ingrezza for Tardive Dyskinesia: Its Safety, Efficacy, and Implication
Author(s)Kevin Kunzmann
Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.
Advertisement
Laxman Bahroo, DO, director of the Botulinum Toxin Clinic and associate professor of Neurology at Georgetown University Hospital, took time out of the 21st International Congress of Parkinson's Disease and Movement Disorders to discuss Ingrezza, the first and only treatment approved for Tardive Dyskinesia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Navigating Emotional Burden in IBD
2
Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD
3
Open Communication Between Patients and Providers in IBD
4
Linaclotide in Pediatric IBS-C—Evidence, Indications, and Practical Use
5
























































































